A South Korean protester wears a mask of President Trump during a rally to demand a U.S. and North Korea summit on May 25, 2018, in Seoul. Photo: Chung Sung-Jun via Getty Images

While high hopes and expectations for the planned Kim–Trump summit in Singapore seemed to vanish yesterday, Trump's letter to Kim left open the possibility to reschedule, and North Korea's reaction was surprisingly humble and flexible, affirming a willingness to meet.

Yes, but: Even if Trump’s North Korea diplomacy ends here, the mere prospect of the June summit has already enhanced Kim’s status on the international stage and conferred legitimacy on his authoritarian regime. Under diplomatic pretenses, North Korea drew China closer to its side after an extended period of tensions, and its relations with South Korea have also significantly improved. Going forward, it will be much more difficult for the U.S. maximum pressure campaign —not to mention U.S. military action — to garner support from these countries.

The abrupt cancellation reveals that Trump lacks a coherent, clever North Korea strategy. Diplomacy is not a business deal, and he cannot afford to be the sole decision-maker. The summit collapse news, which came less than 48 hours after the U.S.–South Korea meeting in Washington, left President Moon, who put every possible effort in brokering the peace process, disappointed and embarrassed.

The U.S.–South Korea alliance could be further damaged if the two sides do not come to a consensus on their North Korea approach. What previously seemed a U.S.–South Korean–Chinese coalition on sanctions against North Korea may turn into a North Korean–South Korean–Chinese coalition against U.S. policies toward the North.

What to watch: Despite the turbulence, neither country is likely to abandon the summit. Both sides have strong, clear political and economic interests in making it happen — Trump’s desire to score a personal victory before the November election and Kim’s desire to lift or ease current sanctions.

The bottom line: Trump needs to show political leadership, not gamesmanship, in coordinating with key stakeholders China and South Korea if he wants to make progress with North Korea.

Gi-Wook Shin is chair of Korean Studies at Stanford University, director of the Walter H. Shorenstein Asia-Pacific Research Center and senior fellow at the Freeman Spogli Institute for International Studies.

Go deeper

49 mins ago - World

Countries waiting to see if Trump wins before moving on Israel normalization

The delegation lands at Israel's Ben Gurion airport. Photo: Jack Guez/AFP via Getty

The White House is attempting to leverage momentum from Israel's normalization deals with Bahrain and the UAE to get more Arab countries on board before the U.S. election.

Driving the news: President Trump wants Sudan's removal from the U.S. state sponsors of terrorism list to be accompanied by a pre-election announcement on Israel.

Poll: 92% of battleground state voters are "extremely motivated to vote"

Voters stand in line at the Metropolitan Multi-Services Center in Houston, Texas, on Oct. 13. Photo: Mark Felix for The Washington Post via Getty Images

91% of likely voters nationally say they are "extremely motivated to vote," including 92% in battleground states Arizona, Florida, Michigan, North Carolina, Pennsylvania and Wisconsin, according to a Change Research/CNBC Poll.

Why it matters: The 2020 election could see record-breaking levels of voter turnout. Voters last week cast ballots at nearly five times the rate they did at this point in the 2016 election, per the U.S. Elections Project. Over 39 million ballots have been cast in early voting states as of Wednesday.

Caitlin Owens, author of Vitals
2 hours ago - Health

OxyContin maker Purdue Pharma to plead guilty to 3 criminal charges

Members of P.A.I.N. (Prescription Addiction Intervention Now) and Truth Pharm staged a rally and die-in last year outside New Yorks Southern District Federal Court in White Plains, where Purdue Pharmaceuticals' bankruptcy hearing was being held. Photo: Erik McGregor/LightRocket via Getty Images

Purdue Pharma, the maker of OxyContin, will plead guilty to three federal criminal charges Wednesday as part of a more than $8 billion settlement with the Justice Department, AP reports.

Why it matters: "The settlement is the highest-profile display yet of the federal government seeking to hold a major drugmaker responsible for an opioid addiction and overdose crisis linked to more than 470,000 deaths in the country since 2000," AP notes.